Showing 2964 results for "hemophilia"

Filter By

UniQure Making Progress Toward US and European Approval of AMT-060 for Hemophilia B

UniQure has taken major steps this year toward U.S. and European regulatory approval of AMT-060, its gene-therapy treatment for hemophilia B. In January, the U.S. Food and Drug Administration (FDA) gave AMT-060 breakthrough therapy designation for patients with severe hemophilia B. In April the European Medicines Agency (EMA) gave it PRIME designation. The designations…

Explaining the Causes of Hemophilia

Hemophilia is a disease where a person blood lacks a factor which enables it to clot. This can lead to severe bleeding which can be life-threatening if left untreated. According to the World Federation of Hemophilia, there are three types of hemophilia: inherited, sporadic, and acquired. MORE: Five…

Could Genome Editing Be a Future Treatment for Hemophilia?

An experimental form of genome editing called clustered regularly interspaced short palindromic repeats or CRISPR/Cas9 could offer a faster and cheaper method of treating people with hemophilia, compared to the current DNA editing method. Because hemophilia is due to DNA mutations, the genome editing could be used to efficiently slice at the DNA,…

Hemophilia and Pregnancy

Family planning and pregnancy for women with hemophilia Women who are hemophilia carriers (women who have a gene mutation in one of their X chromosomes), may have mild bleeding symptoms due to reduced clotting factor levels in their blood. It is important to determine a woman’s carrier status in order to…

BDI Pharma Employees Raise Funds, Awareness on World Hemophilia Day

In recognition of the World Hemophilia Day, BDI Pharma employees company-wide united to raise awareness and money to support those affected by bleeding disorders. Events were held April 17 at the company’s South Carolina, Texas and Kansas sites, with employees joining remotely to raise money to support the WFH (World Federation of Hemophilia) by wearing…

Facts about Hemophilia

In the U.S., hemophilia A is estimated to affect one in every 5,000 male births, hemophilia B one in 25,000 male births, and hemophilia C one in every 100,000 people (males and females). Hemophilia A is thus four times more common than hemophilia B, and about 10 times more common than…

How to Explain Hemophilia to Children

In this simple animated video from CSL Behring US, hemophilia is explained in easy-to-understand language aimed at children and caregivers of newly diagnosed hemophilia patients. MORE: Explaining hemophilia A and hemophilia B The narrator shares the basic difference between hemophilia A and hemophilia B, and that…